Checkpoint inhibitors in cancer therapy | Peter Attia, M.D. & Steven Rosenberg, M.D., Ph.D.

Well SupportedCommon epithelial cancers have low reactivity to checkpoint modulators due to insufficient mutagenic burden.

Partially SupportedCombination treatments using checkpoint modulators may be more effective for cancers with low mutagenic burden.

Partially SupportedCheckpoint inhibitors are easy to apply, requiring only the injection of an antibody.

Partially SupportedCheckpoint inhibitors can be life-saving for some cancer patients but the majority do not respond due to insufficient immune reaction.

Partially SupportedCheckpoint inhibitors only work if there is a tumor antigen for the immune system to recognize.